Brepocitinib | DAILYZ HEALTH NEWS

DAILYZ HEALTH NEWS

ALL ABOUT DAILYZ HEALTH NEWS

DAILYZ HEALTH NEWS

ALL ABOUT DAILYZ HEALTH NEWS

FDA approves oral brepocitinib

August 27, 2026 Evan Vega

FDA approves brepocitinib, the first oral drug for dermatomyositis in adults

The FDA approved LISRAYA (brepocitinib), the first oral TYK2/JAK1 inhibitor for treating adult dermatomyositis, on August 27, 2026.